...
首页> 外文期刊>Journal of biological regulators and homeostatic agents >The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer
【24h】

The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer

机译:粘附分子和趋化因子受体CXCR4(CD184)在小细胞肺癌中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Small-cell lung cancer (SCLC) is a particularly aggressive form of lung cancer. Responsible for this highly malignant phenotype is an early and widespread metastasis with a high propensity of SCLC cells for bone marrow involvement and the ability to develop resistance against chemotherapeutic agents. Tumor cell migration and metastasis share many similarities with leukocyte trafficking, which is critically regulated by chemokines and adhesion molecules. There is growing evidence that the chemokine stromal derived factor-1 (SDF-1/CXCL12) and its receptor CXCR4 (CD184) regulate migration and metastasis of a variety of cancers including SCLC. SCLC cells express high levels of functional CXCR4 receptors. Engagement of CXCR4 by CXCL12 leads to an upregulation of integrin-mediated adhesion in SCLC and other tumor cells. Activation of CXCR4 chemokine receptors and integrins on SCLC cells promotes adhesion to accessory cells (such as stromal cells) and extracellular matrix molecules within the tumor microenvironment. These adhesive interactions result in an increased resistance of SCLC cells to chemotherapy. As such, inhibitors of the CXCR4/CXCL12 axis and/or integrin activation may increase the chemosensitivity of SCLC cells and lead to new therapeutic avenues for patients with SCLC.
机译:小细胞肺癌(SCLC)是肺癌的一种特别侵袭性形式。对这种高度恶性的表型负责的是一种早期且广泛的转移,SCLC细胞倾向于参与骨髓,并且具有对化学治疗剂产生耐药性的能力。肿瘤细胞的迁移和转移与白细胞运输有着许多相似之处,白细胞运输受到趋化因子和粘附分子的严格调节。越来越多的证据表明趋化因子基质衍生因子-1(SDF-1 / CXCL12)及其受体CXCR4(CD184)调节包括SCLC在内的多种癌症的迁移和转移。 SCLC细胞表达高水平的功能性CXCR4受体。 CXCL12与CXCR4的结合导致SCLC和其他肿瘤细胞中整联蛋白介导的粘附的上调。 CLCCR4细胞上CXCR4趋化因子受体和整联蛋白的激活促进了肿瘤微环境中对辅助细胞(例如基质细胞)和细胞外基质分子的粘附。这些粘附相互作用导致SCLC细胞对化学疗法的抗性增加。这样,CXCR4 / CXCL12轴和/或整联蛋白激活的抑制剂可能会增加SCLC细胞的化学敏感性,并为SCLC患者带来新的治疗途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号